Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib
作者: Dorota Kwapisz
作者单位: 1Specialist Outpatient Clinic
刊名: Breast Cancer Research and Treatment, 2017, Vol.166 (1), pp.41-54
来源数据库: Springer Nature Journal
DOI: 10.1007/s10549-017-4385-3
关键词: CDK4/6 inhibitorsBreast cancerPalbociclibRibociclibAbemaciclib
英文摘要: The cyclin D-cyclin dependent kinase (CDK) 4/6-inhibitor of CDK4 (INK4)-retinoblastoma (Rb) pathway plays a crucial role in cell cycle progression and its dysregulation is an important contributor to endocrine therapy resistance. CDK4/6 inhibitors trigger cell cycle arrest in Rb protein (pRb)-competent cells. Recent years have seen the development of selective CDK4/6 inhibitors, which have delivered promising results of efficacy and manageable safety profiles. The main objective of this review is to discuss preclinical and clinical data to date, and ongoing clinical trials with palbociclib, ribociclib, and abemaciclib in breast cancer.
原始语种摘要: The cyclin D-cyclin dependent kinase (CDK) 4/6-inhibitor of CDK4 (INK4)-retinoblastoma (Rb) pathway plays a crucial role in cell cycle progression and its dysregulation is an important contributor to endocrine therapy resistance. CDK4/6 inhibitors trigger cell cycle arrest in Rb protein (pRb)-competent cells. Recent years have seen the development of selective CDK4/6 inhibitors, which have delivered promising results of efficacy and manageable safety profiles. The main objective of this review is to discuss preclinical and clinical data to date, and ongoing clinical trials with palbociclib, ribociclib, and abemaciclib in breast cancer.
全文获取路径: Springer Nature  (合作)
分享到:
来源刊物:
影响因子:4.469 (2012)

×
关键词翻译
关键词翻译
  • kinase 激酶
  • breast 胸部
  • cancer 癌症
  • dependent 从属的
  • retinoblastoma 成视网膜细胞瘤
  • preclinical 临证前期的
  • cyclin 细胞周期蛋白
  • crucial 有决定性的
  • efficacy 效验
  • cycle 旋回